OKYO-0101 is under clinical development by OKYO Pharma and currently in Phase II for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase II drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how OKYO-0101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OKYO-0101 overview

OKYO-0101 is under development for the treatment of dry eye, uveitis, allergic conjunctivitis and neuropathic corneal pain. The drug candidate comprises of 9-amino acid coupled with chemerin peptide. It is administered by ophthalmic route. It is developed based on membrane-tethered ligand technology and membrane-anchored-peptide (MAP) technology. It acts by targeting ChemR23 G-protein coupled receptor.

OKYO Pharma overview

OKYO Pharma, formerly West African Mineral Corporation) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for treating inflammatory dry eye disease and neuropathic corneal pain. The company’s pipeline products include OK-101 which treats dry eye disease, neuropathic corneal pain, allergic conjunctivitis and uveitis; OK-201. It uses membrane-anchored peptide (MAP) technology for the development of pipeline products. The company serves for healthcare providers, medical and pharmaceutical industries. It operates in the US and the UK. OKYO Pharma is headquartered in London, the UK.

For a complete picture of OKYO-0101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 12 April 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.